Close Menu

NEW YORK — Fosun Pharmaceutical said on Thursday that its Fosun Long March Medical Science subsidiary has received emergency approval from China's National Medical Products Administration for a SARS-CoV-2 detection kit.

According to Shanghai, China-based Fosun Pharma, the kit is designed to detect the virus' ORF1ab, N, and E genes, and can proess 96 samples within two hours.

Earlier this month, Fosun Long March received CE marking for its SARS-CoV-2 nucleic acid detection kit, Fosun Pharma said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.